Tuesday, August 19, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Sell Rating on Stellus Capital Investment with Lower Price Target

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On March 6, 2024, Bryce Rowe, an analyst at B. Riley Securities, reaffirmed his Sell rating on Stellus Capital Investment (NYSE: SCM) and adjusted the price target to $12.50, down from $13. This update comes after Stellus Capital Investment was downgraded from Neutral to Sell by B. Riley, citing a changing market environment. The previous price target of $13 has been revised in light of these developments.

SCM Stock Performance Shows Interesting Movements on March 6, 2024

On March 6, 2024, SCM’s stock performance showed some interesting movements. According to data from CNN Money, SCM was trading near the bottom of its 52-week range and below its 200-day simple moving average. This indicates that the stock may be experiencing some downward pressure.

However, on that particular day, there was a slight uptick in the price of SCM shares. The stock had increased by $0.22 since the market last closed, representing a 1.73% rise. This brought the closing price of SCM shares to $12.97.

Despite this initial increase, the stock experienced a drop of $0.09 in pre-market trading. This drop may have been influenced by various factors such as market sentiment, economic indicators, or company-specific news.

SCM Stock Performance Analysis: Revenue Decline and Net Loss Raise Concerns for Investors

On March 6, 2024, SCM stock experienced a mixed performance based on the latest financial data provided by CNN Money. The company’s total revenue for the past year was $78.77 million, a decrease of 9.86% compared to the previous year. However, the total revenue for the third quarter was $27.77 million, showing an increase of 5.67% from the previous quarter.

In terms of net income, SCM reported a net income of $14.49 million for the past year, which represents a significant decrease of 56.83% compared to the previous year. The net income for the third quarter was -$2.40 million, indicating a loss for that period and a decrease of 164.6% from the previous quarter.

Earnings per share (EPS) also saw a decline for SCM stock. The EPS for the past year was $0.74, a decrease of 56.97% compared to the previous year. The EPS for the third quarter was -$0.10, showing a loss per share and a decrease of 160.07% from the previous quarter.

Overall, these financial indicators suggest that SCM stock has faced challenges in terms of revenue, net income, and earnings per share. Investors may be concerned about the company’s performance and future prospects based on these figures. It is important for investors to closely monitor SCM’s financial performance and any updates from the company to make informed decisions about their investments in the stock.

Tags: SCM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Market Today (1)

Harvard Bioscience Inc Unveils CuttingEdge Product Advancements for Research at SOT Conference

The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

BTIG Analyst Gray Powell Optimistic about HashiCorps Future Growth

Groundbreaking Clinical Study Shows Effectiveness of AVIM Therapy in Hypertensive Pacemaker Patients

Recommended

FLO stock news

Visa Reports Impressive Financial Performance in Q1 2024

2 years ago
Finance_Banking (2)

Amerant Bank Announces Asset Sale Agreement with Prime Finance Advisor

2 years ago

Adial Pharmaceuticals Expands Scope of Genetic Diagnostic Technology for Addiction Treatment

2 years ago
Finance_Commercial

Wells Fargo Upgrades Price Target for CrowdStrike Holdings Expresses Bullish Stance

1 year ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Sabra Health Care REIT Demonstrates Resilience with Strong Quarterly Performance

IBM’s Strategic Crossroads: Major Indian Contract Contrasts With AI Security Concerns

Institutional Investors Show Diverging Views on Dish Network’s Future

Institutional Investors Back Rush Enterprises B Despite Earnings Shortfall

Rocket Lab’s Next Mission Sets Stage for Potential Stock Rebound

Navigating Regulatory Crosscurrents: The Shifting Tides for Global Shipping

Trending

Viridian Therapeutics Stock
Stocks

Viridian Therapeutics Faces Financial Crossroads Amid Promising Drug Development

by Dieter Jaworski
August 19, 2025
0

The biotech firm Viridian Therapeutics finds itself at a pivotal financial juncture as it balances promising clinical...

Tilray Stock

Tilray Stock: Regulatory Optimism Meets Market Realities

August 19, 2025
Murphy Oil Stock

Major Investors Divided on Murphy Oil’s Prospects

August 19, 2025
Sabra Health Care Reit Stock

Sabra Health Care REIT Demonstrates Resilience with Strong Quarterly Performance

August 19, 2025
IBM Stock

IBM’s Strategic Crossroads: Major Indian Contract Contrasts With AI Security Concerns

August 19, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Viridian Therapeutics Faces Financial Crossroads Amid Promising Drug Development August 19, 2025
  • Tilray Stock: Regulatory Optimism Meets Market Realities August 19, 2025
  • Major Investors Divided on Murphy Oil’s Prospects August 19, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com